Glucometabolic Control and Anti-Transglutaminase Antibodies at Celiac Disease Onset in Type 1 Diabetes Youth - Scorecard - MDSpire

Glucometabolic Control and Anti-Transglutaminase Antibodies at Celiac Disease Onset in Type 1 Diabetes Youth

  • By

  • Francesca Di Candia

  • Francesco Maria Rosanio

  • Roberto Franceschi

  • Alessandro Fierro

  • Riccardo Bonfanti

  • Francesca Cardella

  • Valentino Cherubini

  • Giuseppe D’Annunzio

  • Barbara Felappi

  • Dario Iafusco

  • Brunella Iovane

  • Claudio Maffeis

  • Giulio Maltoni

  • Francesca Olivieri

  • Gabriele Olivieri

  • Barbara Piccini

  • Elvira Piccinno

  • Barbara Predieri

  • Ivana Rabbone

  • Maria Rossella Ricciardi

  • Giuseppina Salzano

  • Riccardo Schiaffini

  • Gianluca Tornese

  • Angela Zanfardino

  • Marco Marigliano

  • Riccardo Troncone

  • Riccardo Pertile

  • Luigi Greco

  • Renata Auricchio

  • Enza Mozzillo

  • ISPED Diabetes Study Group Collaborators

  • Francesco Gallo

  • Caterina Grosso

  • Carlo Ripoli

  • Fiorella De Berardinis

  • Susanna Coccoli

  • Valentina Tiberi

  • Sonia Toni

  • Maurizio Delvecchio

  • Rosanna Roppolo

  • Fortunato Lombardo

  • Stefano Passanisi

  • Bruno Bombaci

  • Alberto Casertano

  • Nicola Minuto

  • Marta Bassi

  • Evelina Maines

  • Silvia Savastio

  • Elena Inzaghi

  • Andrea Rigamonti

  • Giulio Frontino

  • Patrizia Bruzzi

  • Claudia Piona

  • November 4, 2025

  • 0 min

Share

Clinical Scorecard: Association of Glucometabolic Parameters and Anti-Transglutaminase Antibodies at the Onset of Celiac Disease in Youth with Type 1 Diabetes

At a Glance

CategoryDetail
ConditionCeliac disease (CD) in children and adolescents with type 1 diabetes (T1D)
Key MechanismsCorrelation of anti-transglutaminase IgA antibodies (anti-TTG IgA) titers with mucosal damage and glucometabolic control (HbA1c) at CD diagnosis
Target PopulationChildren and adolescents aged 0-20 years with T1D and newly diagnosed CD
Care SettingPediatric diabetes and gastroenterology centers

Key Highlights

  • Higher anti-TTG IgA titers correlate with worse mucosal damage (Marsh grade) and poorer glycemic control (HbA1c) at CD diagnosis in youths with T1D.
  • An anti-TTG IgA cutoff of 11 times the upper limit of normal (ULN) is optimal for sparing biopsy in T1D-CD patients, slightly higher than in the general pediatric population.
  • Individuals with both T1D and CD have a higher prevalence of autoimmune comorbidities, especially when CD precedes T1D, suggesting mandatory screening for T1D in CD patients.

Guideline-Based Recommendations

Diagnosis

  • Screen youths with T1D for CD using anti-TTG IgA antibodies at T1D onset and every 1-2 years thereafter or if symptoms/family history arise (ISPAD).
  • Use biopsy-free diagnosis for CD in children with anti-TTG IgA ≥10x ULN and positive anti-endomysial IgA antibody confirmation (ESPGHAN).
  • In T1D-CD patients, consider an anti-TTG IgA cutoff of 11x ULN for biopsy sparing.

Management

  • Adhere to gluten-free diet (GFD) upon CD diagnosis to prevent mucosal damage and improve metabolic control.
  • Monitor glycemic control closely in T1D-CD patients, as worse HbA1c is associated with higher anti-TTG IgA and mucosal damage.

Monitoring & Follow-up

  • Regularly monitor anti-TTG IgA titers and HbA1c levels at CD diagnosis and during follow-up to assess disease activity and metabolic control.
  • Screen for additional autoimmune comorbidities in T1D-CD patients, especially those with CD preceding T1D.

Risks

  • Risk of mucosal damage correlates with higher anti-TTG IgA titers and poor glycemic control.
  • Delayed or missed CD diagnosis in T1D patients may lead to increased autoimmune comorbidities and complications.

Patient & Prescribing Data

Children and adolescents with T1D and newly diagnosed CD

Early diagnosis using anti-TTG IgA cutoff of 11x ULN can reduce need for biopsy; strict GFD adherence and glycemic control are critical to reduce mucosal damage and improve outcomes.

Clinical Best Practices

  • Implement routine anti-TTG IgA screening at T1D diagnosis and periodically thereafter.
  • Use anti-TTG IgA ≥11x ULN as a threshold for biopsy-free CD diagnosis in T1D patients, with confirmatory testing.
  • Screen CD patients for T1D, especially when CD precedes diabetes onset.
  • Monitor and manage glycemic control aggressively in T1D-CD patients to mitigate mucosal damage.
  • Assess and monitor for other autoimmune comorbidities in patients with dual diagnosis.

References

Original Source(s)

Glucometabolic Control and Anti-Transglutaminase Antibodies at Celiac Disease Onset in Type 1 Diabetes Youth

  • by Francesca Di Candia, Francesco Maria Rosanio, Roberto Franceschi, Alessandro Fierro, Riccardo Bonfanti, Francesca Cardella, Valentino Cherubini, Giuseppe D’Annunzio, Barbara Felappi, Dario Iafusco, Brunella Iovane, Claudio Maffeis, Giulio Maltoni, Francesca Olivieri, Gabriele Olivieri, Barbara Piccini, Elvira Piccinno, Barbara Predieri, Ivana Rabbone, Maria Rossella Ricciardi, Giuseppina Salzano, Riccardo Schiaffini, Gianluca Tornese, Angela Zanfardino, Marco Marigliano, Riccardo Troncone, Riccardo Pertile, Luigi Greco, Renata Auricchio, Enza Mozzillo, ISPED Diabetes Study Group Collaborators, Francesco Gallo, Caterina Grosso, Carlo Ripoli, Fiorella De Berardinis, Susanna Coccoli, Valentina Tiberi, Sonia Toni, Maurizio Delvecchio, Rosanna Roppolo, Fortunato Lombardo, Stefano Passanisi, Bruno Bombaci, Alberto Casertano, Nicola Minuto, Marta Bassi, Evelina Maines, Silvia Savastio, Elena Inzaghi, Andrea Rigamonti, Giulio Frontino, Patrizia Bruzzi, Claudia Piona

  • November 4, 2025

Related Content

Metformin’s Potential Role in Posterior Capsule Opacification

Common diabetes therapy reaches intraocular lens tissue and may help limit PCO, says newly published data

  • March 30, 2026

  • 3 min
Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience

Hospital Prices Posted. Few Patients Look.

Federal rules require hospitals to post prices so patients can shop. Instead, insurers and providers use the data to negotiate what they get paid.